Noul brings AI cervical cancer screening technology to Indonesia

Korean medtech firm Noul has entered the Indonesian market by signing its first supply agreement for an automated cervical cancer screening system. This comes as Indonesia works to expand its preventive care measures. The agreement was signed with a local medical device distributor, and Noul plans to supply at least 50 miLab CER units to Indonesian medical institutions and laboratory networks over a period of three years.

Noul stated that it will initially focus on working with hospitals, screening centers, and laboratory networks before exploring opportunities in Indonesia's public procurement market. The company has already secured regulatory approvals for its miLab CER system in several Southeast Asian countries, including Vietnam and the Philippines, which will serve as a foundation for further expansion across the region.

With a population of about 280 million, Indonesia represents the largest healthcare market in Southeast Asia, according to Noul. The company highlighted that cervical cancer poses a significant burden on women in the country, and Indonesia plans to incorporate cervical cancer screening into its healthcare system.